Big Pharma Leaders Show United Front On COVID-19
Lilly CEO Warns Against Trump-Style Unilateralism
Costs will be an issue, but not today; industry and healthcare systems are working at breakneck speed to catch up with the deadly virus.
You may also be interested in...
US major continues its expansion in oncology with an early stage deal with Flagship Pioneering protegés.
The Bayesian adaptive trial design is looking to slash development times, starting with a Phase II trial of Ridgeback’s drug, a potential challenger to Gilead’s remdesivir.
Novavax has progressed into Phase I trials with relatively little funding, but backing from Operation Warp Speed makes it a stronger contender.